In the world of unproven regenerative medicine, the warning signs are rarely crude. They are polished. They are carefully worded. They speak of science, hope, recovery, and breakthroughs. And that is exactly why companies operating in this space deserve close scrutiny.
In any major investigation, there comes a moment when the reaction from those under scrutiny says more than the evidence itself. In the global stem cell treatment industry—now worth billions—those moments are becoming increasingly frequent.